The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ryabchenko E.V.

Regional Clinical Hospital No. 2

Dremlyuga N.V.

Regional Clinical Hospital No. 2

Mezhinskaya E.M.

Regional Clinical Hospital No. 2

Polyansky E.A.

Regional Clinical Hospital No. 2

Pheochromocytoma associated with primary hyperparathyroidism and type 1 neurofibromatosis

Authors:

Ryabchenko E.V., Dremlyuga N.V., Mezhinskaya E.M., Polyansky E.A.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2023;(7): 120‑127

Read: 2218 times


To cite this article:

Ryabchenko EV, Dremlyuga NV, Mezhinskaya EM, Polyansky EA. Pheochromocytoma associated with primary hyperparathyroidism and type 1 neurofibromatosis. Pirogov Russian Journal of Surgery. 2023;(7):120‑127. (In Russ.)
https://doi.org/10.17116/hirurgia2023071120

Recommended articles:
Difficulties of diagnosing a clinically silent pheochromocytoma. Russian Journal of Preventive Medi­cine. 2025;(3):107-111
Anatomical and clinical substantiation of the opti­mal technique of mini­mally inva­sive para­thyroidectomy. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2):22-29

References:

  1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: A multidisciplinary approachtocare. Lancet Neurology. 2014;13:834-843.  https://doi.org/10.1016/S1474-4422(14)70063-8
  2. Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Laboratory Investigation. 2017;97:146-157.  https://doi.org/10.1038/labinvest.2016.142
  3. Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nature Reviews Cancer. 2015;15:290-301.  https://doi.org/10.1038/nrc3911
  4. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen’s disease and pheochromocytomas. Journal of Urology. 1999;162:1582-1586. https://doi.org/10.1016/S0022-5347(05)68171-2
  5. Zöller M, Rembeck B, Odén A, Samuelsson M, Angervall L. Malignant and benign tumours in patients with neurofibromatosis type 1 in a defined Swedish population. American Cancer Society. 1997;79:2125-2131. https://doi.org/10.1002/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N
  6. Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, Giustini S, Sciomer S, Anastasi E, Calvieri S, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Archives of Dermatological Research. 2011;303:317-325.  https://doi.org/10.1007/s00403-010-1090-z
  7. Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF Jr, Bancos I. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clinical Endocrinology. 2017;86:141-149.  https://doi.org/10.1111/cen.13163
  8. Austin E, Bates A. Association of neurofibromatosis type 1 with primary hyperparathyroidism: report of a case. Endocrine Abstracts. 2016;44:EP25. https://doi.org/10.1530/endoabs.44.EP25
  9. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. Journal of Medical Genetics. 2007;44:81-88.  https://doi.org/10.1136/jmg.2006.045906
  10. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Archives of Neurology. 1988;45:575-578. 
  11. Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist. 2012;17:101-116.  https://doi.org/10.1634/theoncologist.2010-0181
  12. Menon RK, Ferrau F, Kurzawinski TR, Rumsby G, Freeman A, Amin Z, Korbonits M, Chung T-TLL. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. Endocrinology, Diabetes and Metabolism Case Reports. 2014;2014:140074. https://doi.org/10.1530/EDM-14-0074
  13. Képénékian L, Mognetti T, Lifante JC, Giraudet AL, Houzard C, Pinson S, Borson-Chazot F, Combemale P. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. European Journal of Endocrinology. 2016;175:335-344.  https://doi.org/10.1530/EJE-16-0233
  14. Bausch B, Borozdin W, Neumann HP & European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. New England Journal of Medicine. 2006;354:2729-2731. https://doi.org/10.1056/NEJMc066006
  15. Shinall MC, Solórzano CC. Pheochromocytoma in neurofibromatosis type 1: when should it be suspected? Endocrine Practice. 2014;20:792-796.  https://doi.org/10.4158/EP13417.OR
  16. Moramarco J, El Ghorayeb N, Dumas N, Nolet S, Boulanger L, Burnichon N, Lacroix A, Elhaffaf Z, Gimenez Roqueplo AP, Hamet P, et al. Pheochromocytomas are diagnosed incidentally and at older age in neurofibromatosis type 1. Clinical Endocrinology. 2017;86:332-339.  https://doi.org/10.1111/cen.13265
  17. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry. 2011;57:411-420.  https://doi.org/10.1373/clinchem.2010.153320
  18. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr & Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2014;99:1915-1942. https://doi.org/10.1210/jc.2014-1498
  19. Chakrabarti S, Murugesan A, Arida EJ. The association of neurofibromatosis and hyperparathyroidism. American Journal of Surgery. 1979;137:417-420.  https://doi.org/10.1016/0002-9610(79)90079-5
  20. Favere AM, Tsukumo DM, Matos PS, Santos SL, Lalli CA. Association between atypical parathyroid adenoma and neurofibromatosis. Archives of Endocrinology and Metabolism. 2015;59:460-466.  https://doi.org/10.1590/2359-3997000000092
  21. Behera KK, Nanaiah A, Gupta A, Rajaratnam S. Neurofibromatosis type 1, pheochromocytoma with primary hyperparathyroidism: A rare association. Indian Journal of Endocrinology and Metabolism. 2013;17:349-351.  https://doi.org/10.4103/2230-8210.109670
  22. Al-Wahhabi B. Parathyroid adenoma and bilateral pheochromocytoma in a patient with neurofibromatosis. Annals of Saudi Medicine. 2005:255-257.  https://doi.org/10.5144/0256-4947.2005.255
  23. Lodish MB, Dagalakis U, Sinaii N, Bornstein E, Kim A, Lokie KB, Baldwin AM, Reynolds JC, Dombi E, Stratakis CA, et al Bone mineral density in children and young adults with neurofibromatosis type 1. Endocrine-Related Cancer. 2012;19:817-825.  https://doi.org/10.1530/ERC-12-0293
  24. Brunetti-Pierr N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, et al. Generalized metabolic bone disease in neurofibromatosis type I. Molecular Genetics and Metabolism. 2008;94:105-111.  https://doi.org/10.1016/j.ymgme.2007.12.004
  25. Bilezikian P1, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT, Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism. 2014;99:3561-3569. https://doi.org/10.1210/jc.2014-1413
  26. Altinova AE, Toruner FA, Cimen R, Karakoc A, Atasever T, Yetkin I, Ayvaz G, Cakir N, Arslan M. The association of neurofibromatosis, bilateral pheochromocytoma and primary hyperparathyroidism. Experimental and Clinical Endocrinology and Diabetes. 2007;115:468-470.  https://doi.org/10.1055/s-2007-981661
  27. Gkaliagkousi E, Erlic Z, Petidis K, Semertzidis P, Doumas M, Zamboulis C, Neumann HP, Douma S. Neurofibromatosis type 1: should we screen for other genetic syndromes? A case report of co-existence with multiple endocrine neoplasia 2A. European Journal of Clinical Investigation. 2009;39:828-832.  https://doi.org/10.1111/j.1365-2362.2009.02174.x
  28. Cotesta D, Erlic Z, Petramala L, Verrienti A, Cavallaro G, Giustini S, Divona L, Polistena A, Ciardi A, D’Erasmo E, et al. Coincidence of neurofibromatosis type 1 and multiple endocrine neoplasia type 2  (MEN 2). Endocrinologist. 2008;18:277-281.  https://doi.org/10.1097/TEN.0b013e3181913188
  29. Ercolino T, Lai R, Giachè V, Melchionda S, Carella M, Delitala A, Mannelli M, Fanciulli G. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. Gene. 2014;536:332-335.  https://doi.org/10.1016/j.gene.2013.12.003
  30. Mon A, Malipatil N, Sharma D, Afta R, Koay Y, Whittingham P, Hamilton A, Vora J. A patient with neurofibromatosis type-1 (NF1). Abstracts. 2009;19:P175. https://doi.org/10.1038/nrc3911
  31. Diazzi C, Guidi A, Luberto A, Taliani E, Madeo B, Rochira V, Carani C. Thyroid disease in patients with type-1 neurofibromatosis: An underestimated issue? Endocrine Abstracts. 2011;26:P452. https://doi.org/10.1210/endomeetings

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.